Lexaria regains Nasdaq bid price compliance; hearing cancelled, stock remains listed

Lexaria Bioscience Corp.

Received Nasdaq letter on Aug 17, 2026 confirming compliance with Rule 5550(a)(2) bid price requirement.
Previously requested hearing before Nasdaq Hearings Advisor has been cancelled.
Common stock (LEXX) continues trading on The Nasdaq Capital Market without interruption.

Featured in Daily 8-K Digest

Selected #8 for 2026-08-17. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.